Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Fuso: Profits Marked for 1st Time in 3 Years
December 1, 2003
- SEMI-ANNUAL BUSINES RESULTS
December 1, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
November 24, 2003
- Santen: Overall Sales Down Slightly from Sluggish Domestic Sales
November 24, 2003
- Statement on Proper Use of Iressa Issued by JLCS
November 24, 2003
- Ono: Sales Increase 2.8%, Profits Up 3.9%
November 24, 2003
- Micardis Exerts Hypotensive Effects for 24-hour: JSH Meeting
November 24, 2003
- Dainippon: Rapid Drop in Sales of Gatiflo Hurts Sales, Profits
November 24, 2003
- Home Blood Pressure GL Compiled by JSH
November 24, 2003
- Tanabe Seiyaku: 9.7% Increase in Net Profits Despite Sales Drop
November 24, 2003
- NEW PRODUCTS
November 24, 2003
- Shionogi: Sales Plunge 44.3%, but Profits Up
November 24, 2003
- Japan Adult Guardianship Law Association Inaugurated
November 24, 2003
- Chugai: Cost-cutting Efforts Produce Better-than-Expected Profits
November 24, 2003
- REGULATORY NEWS IN BRIEF
November 24, 2003
- Yamanouchi: Sales Up 2.8%, Attributable to Sales Growth of Harnal, Lipitor
November 24, 2003
- Council for Regulatory Reform May Be Replaced with More Powerful Machine: Mr Miyauchi
November 24, 2003
- Sankyo: Mevalotin Boosts Domestic, Overseas Sales
November 24, 2003
- FPMAJ Wants Gov't to Maintain Price Reduction Rules for Long-Listed Drugs
November 24, 2003
- Semi-annual Business Results
November 24, 2003
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…